200 related articles for article (PubMed ID: 27356024)
21. The economics of multiple sclerosis. Distribution of costs and relationship to disease severity.
Grudzinski AN; Hakim Z; Cox ER; Bootman JL
Pharmacoeconomics; 1999 Mar; 15(3):229-40. PubMed ID: 10537431
[TBL] [Abstract][Full Text] [Related]
22. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada.
Karampampa K; Gustavsson A; Miltenburger C; Kindundu CM; Selchen DH
J Popul Ther Clin Pharmacol; 2012; 19(1):e11-25. PubMed ID: 22247419
[TBL] [Abstract][Full Text] [Related]
23. Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents.
Amato MP
Expert Opin Pharmacother; 2004 Oct; 5(10):2115-26. PubMed ID: 15461547
[TBL] [Abstract][Full Text] [Related]
24. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment.
Phillips CJ
CNS Drugs; 2004; 18(9):561-74. PubMed ID: 15222773
[TBL] [Abstract][Full Text] [Related]
25. Current and emerging treatment of multiple sclerosis.
Hart FM; Bainbridge J
Am J Manag Care; 2016 Jun; 22(6 Suppl):s159-70. PubMed ID: 27356025
[TBL] [Abstract][Full Text] [Related]
26. The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil.
Maia Diniz I; Guerra AA; Lovato Pires de Lemos L; Souza KM; Godman B; Bennie M; Wettermark B; de Assis Acurcio F; Alvares J; Gurgel Andrade EI; Leal Cherchiglia M; de Araújo VE
PLoS One; 2018; 13(6):e0199446. PubMed ID: 29928006
[TBL] [Abstract][Full Text] [Related]
27. Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US.
Jones E; Pike J; Marshall T; Ye X
BMC Health Serv Res; 2016 Jul; 16():294. PubMed ID: 27443278
[TBL] [Abstract][Full Text] [Related]
28. [Cost of multiple sclerosis in France].
Fromont A; Lehanneur MN; Rollot F; Weill A; Clerc L; Bonithon Kopp C; Binquet C; Moreau T
Rev Neurol (Paris); 2014; 170(6-7):432-9. PubMed ID: 24856285
[TBL] [Abstract][Full Text] [Related]
29. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
30. Determinants of high cost in multiple sclerosis patients: a claims and chart review study.
Ke X; Navaratnam P; Sasane R; Eisenberg Lawrence DF; Friedman HS; Tulsi BB; Vollmer T
Curr Med Res Opin; 2016 Sep; 32(9):1589-97. PubMed ID: 27207562
[TBL] [Abstract][Full Text] [Related]
31. Pharmacoeconomics of synthetic therapies for multiple sclerosis.
D'Amico E; Chisari CG; Gitto L; Zanghì A; Toscano S; Patti F
Expert Opin Pharmacother; 2019 Aug; 20(11):1331-1340. PubMed ID: 31090469
[No Abstract] [Full Text] [Related]
32. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.
Hawton A; Shearer J; Goodwin E; Green C
Appl Health Econ Health Policy; 2013 Aug; 11(4):331-41. PubMed ID: 23637055
[TBL] [Abstract][Full Text] [Related]
33. Multiple sclerosis: relapses, resource use, and costs.
Hawton AJ; Green C
Eur J Health Econ; 2016 Sep; 17(7):875-84. PubMed ID: 26438399
[TBL] [Abstract][Full Text] [Related]
34. The economic cost of multiple sclerosis in Sweden in 1994.
Henriksson F; Jönsson B
Pharmacoeconomics; 1998 May; 13(5 Pt 2):597-606. PubMed ID: 17165326
[TBL] [Abstract][Full Text] [Related]
35. Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis.
Dunn J
Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):433-40. PubMed ID: 20482233
[TBL] [Abstract][Full Text] [Related]
36. Predictors of the 10-year direct costs for treating multiple sclerosis.
Moccia M; Palladino R; Lanzillo R; Triassi M; Brescia Morra V
Acta Neurol Scand; 2017 May; 135(5):522-528. PubMed ID: 27357245
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
O'Day K; Meyer K; Miller RM; Agarwal S; Franklin M
J Med Econ; 2011; 14(5):617-27. PubMed ID: 21777161
[TBL] [Abstract][Full Text] [Related]
38. Multiple sclerosis care: an integrated disease-management model.
Burks J
J Spinal Cord Med; 1998 Apr; 21(2):113-6. PubMed ID: 9697085
[TBL] [Abstract][Full Text] [Related]
39. Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers.
Parisé H; Laliberté F; Lefebvre P; Duh MS; Kim E; Agashivala N; Abouzaid S; Weinstock-Guttman B
J Neurol Sci; 2013 Jul; 330(1-2):71-7. PubMed ID: 23647840
[TBL] [Abstract][Full Text] [Related]
40. Economic evaluation of multiple sclerosis in the UK, Germany and France.
Murphy N; Confavreux C; Haas J; König N; Roullet E; Sailer M; Swash M; Young C; Mérot JL;
Pharmacoeconomics; 1998 May; 13(5 Pt 2):607-22. PubMed ID: 17165327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
